Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912239182> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2912239182 abstract "Introduction: Tissue plasminogen activator (Alteplase; tPA) is the most commonly used thrombolytic medication for treatment of acute ischemic stroke, and recent research suggests that Tenecteplase (TNKase) is also effective. NA-1 is a novel neuroprotective drug intended to reduce disability when administered after stroke that is currently being studied in two late stage clinical trials, FRONTIER (NCT02315443) and ESCAPE-NA1 (NCT02930018). Given the overlap in the patient populations and the likelihood that subjects receiving NA-1 could receive thrombolysis, studies were performed to evaluate the effects of NA-1 on the fibrinolytic activity of tPA and TNKase. Methods: A spectrophotometric method of measuring clot formation and lysis in citrated human plasma was developed and used to assess the fibrinolytic activity of tPA and of TNKase. Aprotinin, a known protease inhibitor capable of blocking tPA and TNKase activity, was used as a positive control to demonstrate that the assay system was appropriately sensitive to detect inhibition of thrombolytic activity. Varying concentrations of NA-1 were added to the reaction to assess whether NA-1 could affect the rate of clot formation or the rate of clot lysis in the presence of tPA or TNKase. Results: The sensitivity of this assay system was demonstrated to enable detection of small changes in the fibrinolytic activity of tPA and TNKase on human plasma in the presence of thrombin. NA-1 did not display any fibrinolytic activity on its own nor did it affect the rate of clot formation in the system. NA-1 also did not affect the rate of clot formation or of fibrinolysis in the presence of tPA or TNKase. Conclusions: NA-1 has no intrinsic fibrinolytic activity and does not modulate the fibrinolytic activity of tPA or TNKase. Therefore, NA-1 can be given safely to stroke victims receiving tPA or TNKase without negatively impacting the potential benefit of thrombolysis. This method could also be used to assess other drugs that may have the potential to interact with or be concurrently administered to patients receiving thrombolytic medications." @default.
- W2912239182 created "2019-02-21" @default.
- W2912239182 creator A5018456621 @default.
- W2912239182 creator A5029911724 @default.
- W2912239182 creator A5078197541 @default.
- W2912239182 date "2019-02-01" @default.
- W2912239182 modified "2023-09-25" @default.
- W2912239182 title "Abstract 80: The Experimental Neuroprotective Drug Na1 Does Not Interfere With the Fibrinolytic Activities of Alteplase or Tenecteplase" @default.
- W2912239182 doi "https://doi.org/10.1161/str.50.suppl_1.80" @default.
- W2912239182 hasPublicationYear "2019" @default.
- W2912239182 type Work @default.
- W2912239182 sameAs 2912239182 @default.
- W2912239182 citedByCount "0" @default.
- W2912239182 crossrefType "journal-article" @default.
- W2912239182 hasAuthorship W2912239182A5018456621 @default.
- W2912239182 hasAuthorship W2912239182A5029911724 @default.
- W2912239182 hasAuthorship W2912239182A5078197541 @default.
- W2912239182 hasConcept C126322002 @default.
- W2912239182 hasConcept C127413603 @default.
- W2912239182 hasConcept C25498285 @default.
- W2912239182 hasConcept C2776572282 @default.
- W2912239182 hasConcept C2776825266 @default.
- W2912239182 hasConcept C2777377995 @default.
- W2912239182 hasConcept C2779095551 @default.
- W2912239182 hasConcept C2779581417 @default.
- W2912239182 hasConcept C2779679481 @default.
- W2912239182 hasConcept C2780645631 @default.
- W2912239182 hasConcept C2780790693 @default.
- W2912239182 hasConcept C2780799893 @default.
- W2912239182 hasConcept C2909373784 @default.
- W2912239182 hasConcept C2909817843 @default.
- W2912239182 hasConcept C500558357 @default.
- W2912239182 hasConcept C71924100 @default.
- W2912239182 hasConcept C78519656 @default.
- W2912239182 hasConcept C98274493 @default.
- W2912239182 hasConceptScore W2912239182C126322002 @default.
- W2912239182 hasConceptScore W2912239182C127413603 @default.
- W2912239182 hasConceptScore W2912239182C25498285 @default.
- W2912239182 hasConceptScore W2912239182C2776572282 @default.
- W2912239182 hasConceptScore W2912239182C2776825266 @default.
- W2912239182 hasConceptScore W2912239182C2777377995 @default.
- W2912239182 hasConceptScore W2912239182C2779095551 @default.
- W2912239182 hasConceptScore W2912239182C2779581417 @default.
- W2912239182 hasConceptScore W2912239182C2779679481 @default.
- W2912239182 hasConceptScore W2912239182C2780645631 @default.
- W2912239182 hasConceptScore W2912239182C2780790693 @default.
- W2912239182 hasConceptScore W2912239182C2780799893 @default.
- W2912239182 hasConceptScore W2912239182C2909373784 @default.
- W2912239182 hasConceptScore W2912239182C2909817843 @default.
- W2912239182 hasConceptScore W2912239182C500558357 @default.
- W2912239182 hasConceptScore W2912239182C71924100 @default.
- W2912239182 hasConceptScore W2912239182C78519656 @default.
- W2912239182 hasConceptScore W2912239182C98274493 @default.
- W2912239182 hasIssue "Suppl_1" @default.
- W2912239182 hasLocation W29122391821 @default.
- W2912239182 hasOpenAccess W2912239182 @default.
- W2912239182 hasPrimaryLocation W29122391821 @default.
- W2912239182 hasRelatedWork W2011715830 @default.
- W2912239182 hasRelatedWork W2070507091 @default.
- W2912239182 hasRelatedWork W2087950998 @default.
- W2912239182 hasRelatedWork W2090952370 @default.
- W2912239182 hasRelatedWork W2097144485 @default.
- W2912239182 hasRelatedWork W2500172526 @default.
- W2912239182 hasRelatedWork W2912239182 @default.
- W2912239182 hasRelatedWork W3126313021 @default.
- W2912239182 hasRelatedWork W3146025439 @default.
- W2912239182 hasRelatedWork W4322627880 @default.
- W2912239182 hasVolume "50" @default.
- W2912239182 isParatext "false" @default.
- W2912239182 isRetracted "false" @default.
- W2912239182 magId "2912239182" @default.
- W2912239182 workType "article" @default.